Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03153462
Title Axicabtagene Ciloleucel Expanded Access Study
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Kite Pharma, Inc.
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

non-Hodgkin lymphoma

Therapies

axicabtagene ciloleucel + Cyclophosphamide + Fludarabine

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.